Finerenone for liver cirrhosis with fluid buildup and kidney protection
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests whether a medication called finerenone can safely help patients with fatty liver disease that has progressed to cirrhosis (scarring) with fluid buildup in the belly, while also protecting their kidneys from damage.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age between 18 and 80 years old
- Diagnosed with metabolic dysfunction-associated fatty liver disease (MASLD or NAFLD) that has progressed to cirrhosis with visible fluid buildup in the abdomen
- Kidney function measured as stable and adequate (eGFR greater than 60)
- No history of high blood pressure, severe bleeding problems, recent heart attack, or stroke
- Not currently pregnant, nursing, or receiving cancer or immune-suppressing treatments
- Not actively abusing drugs or alcohol, and no uncontrolled diabetes
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a once-daily pill called finerenone to see if it can reduce protein in the urine (a sign of kidney damage) in people with type 2 diabetes and chronic kidney disease. It may help protect your kidneys and slow down disease progression.
This trial tests if finerenone can protect kidneys in people with chronic kidney disease who are not taking common blood pressure medications called ACE inhibitors, ARBs, or renin inhibitors. It may help slow kidney damage.
This study tests whether a medication called finerenone can reduce scarring in the heart and improve heart function in people with heart failure who have ejection fractions of 40% or higher. You may be eligible if you've recently had heart failure symptoms requiring emergency care or medication changes.
This study tests whether finerenone, a new type of drug, can help people with heart failure who cannot take standard steroid-based MRAs (a kind of heart medication) because of side effects or other reasons. It aims to see if it improves symptoms and is safe for you.
This trial tests a medication called finerenone to see if it helps people hospitalized for heart failure live longer and have fewer heart-related problems. It may be an option for those with a certain type of heart failure where the heart's pumping strength is mildly reduced or normal.
This trial tests whether adding finerenone to your current diabetes medications can better protect your heart and kidneys. It is for people with type 2 diabetes who already take an SGLT2 inhibitor and an ACE inhibitor or ARB.
Hear when a new MASLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.